WallStreetZenWallStreetZen

NASDAQ: MLYS
Mineralys Therapeutics Inc Stock Ownership - Who owns Mineralys Therapeutics?

Insider buying vs selling

Have Mineralys Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
David Malcom RodmanChief Medical Officer2024-04-126,349$1.08
$6.86kBuy
David Malcom RodmanChief Medical Officer2024-04-115,017$0.54
$2.71kBuy
David Malcom RodmanChief Medical Officer2024-03-126,348$1.08
$6.86kBuy
David Malcom RodmanChief Medical Officer2024-03-115,017$0.54
$2.71kBuy
Srinivas AkkarajuDirector2024-02-12555,555$13.50
$7.50MBuy
Ra Capital Management LPDirector2024-02-121,672,508$13.50
$22.58MBuy
David Malcom RodmanChief Medical Officer2024-02-126,349$1.08
$6.86kBuy
David Malcom RodmanChief Medical Officer2024-02-125,017$0.54
$2.71kBuy
Samsara Biocapital GP LLC10% Owner2024-02-12555,555$13.50
$7.50MBuy
David Malcom RodmanChief Medical Officer2024-01-126,348$1.08
$6.86kBuy

1 of 3

MLYS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when MLYS insiders and whales buy or sell their stock.

MLYS Shareholders

What type of owners hold Mineralys Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Catalys Pacific LLC18.53%9,194,579$102.43MInstitution
Brian Taylor Slingsby18.53%9,194,579$102.43MInsider
Samsara Biocapital GP LLC10.23%5,074,916$56.53MInsider
Srinivas Akkaraju10.23%5,074,916$56.53MInsider
Samsara Biocapital LLC9.11%4,519,361$50.35MInstitution
Hbm Healthcare Investments Cayman Ltd6.48%3,218,106$35.85MInsider
Ra Capital Management LP6.40%3,178,476$35.41MInsider
Ra Capital Management LP6.40%3,178,476$35.41MInstitution
Adams Street Partners LLC4.64%2,302,329$25.65MInstitution
Braidwell LP4.08%2,023,900$22.55MInstitution

1 of 3

MLYS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
MLYS56.06%43.94%Net BuyingNet Buying
ALLO60.41%39.59%Net SellingNet Selling
VERV62.25%37.75%Net BuyingNet Selling
OLMA71.71%28.29%Net BuyingNet Selling
PRME32.55%67.45%Net BuyingNet Buying

Mineralys Therapeutics Stock Ownership FAQ

Who owns Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ: MLYS) is owned by 69.94% institutional shareholders, 54.82% Mineralys Therapeutics insiders, and 0.00% retail investors. Brian Taylor Slingsby is the largest individual Mineralys Therapeutics shareholder, owning 9.19M shares representing 18.53% of the company. Brian Taylor Slingsby's Mineralys Therapeutics shares are currently valued at $105.09M.

If you're new to stock investing, here's how to buy Mineralys Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.